


A US Patient Perspective on the **Diagnosis and Burden of AxSpA**



228
US patients with axSpA participated in the survey



Following first onset of symptoms, participants waited on average **8.8** years to be diagnosed

On average, women waited **6 years longer** than men to be diagnosed

The content provided herein is for your background and educational purposes only. The material is for your sole use and may not be altered or further disseminated in any fashion for further use.

US Patient Journey to AxSpA Diagnosis

Participants misdiagnosed before receiving an axSpA diagnosis



^aMisdiagnosed conditions in >5% of patients. Patients could have reported >1 misdiagnosis.

Participants diagnosed by a rheumatologist:




Patients were seen by an average of **3** health care providers before receiving their axSpA diagnosis

Most patients saw a primary care physician or general practitioner before receiving an axSpA diagnosis, with **back pain, stiffness, and joint pain**, the axSpA-related symptoms that most commonly initiated a visit to a health care practitioner.

axSpA, axial spondyloarthritis.
Magrey M, Wlash JA, Flierl S, et al. *ACR Open Rheumatol.* 2023;5(5): 264–276.

Most participants (78.9%) had moderate or high disease activity^b

Patients with moderate or high disease activity^b had a **greater spinal stiffness** than those with low disease activity




^bBoth Ankylosing Spondylitis Disease Activity Index score ≥4

Psychological Distress^c Is Common in Patients With AxSpA

Psychological distress was reported by **57.0%** of participants, with similar proportions found between men and women

Patients with moderate or high disease activity were more likely to experience **psychological distress** than those with low disease activity




^cGeneral Health Questionnaire-12 score ≥3

AxSpA Can Have a Considerable Impact on Sleep Quality




Participants reported that axSpA negatively impacted sleep quality and duration



Comorbidities are common in axSpA

Participants reported an average of **5.6** comorbidities



Developed through a collaboration between Novartis Pharma AG and the Axial Spondyloarthritis International Federation (ASIF). As of January 2, 2024, IMAS is owned solely by ASIF, following an in-kind donation to the project by Novartis Pharma AG. Novartis and ASIF agreed to the use of new materials after the date of transfer of ownership.